Table 10.

Summary of Naltrexone (NTX) Efficacy and Safety in Pediatric Trials in Eating Disorders

Reference	Sample Size (Study Design)	Dosing and Duration	Outcome
Chatoor93	1 (case study, PCT)	15-yr–old with BN – NTX: Up to 100 mg/day for 8 days	Urge scores: NTX: 1.5 (CV 33%); PLB: 4.5 SAE: none
Stancil15	33 (retrospective case series)	Adolescents with AN-BP and BN –NTX: up to 100 mg/day, mean duration 129 days	Reduced urges and behaviors: 67% of participants CGI-I score: mean: 2.7 (CV 48%) SAE: none
Raingeard12	10 (open-label)	Mean age, 22 yr; range, 17–29 yr with type 1 diabetes and BN/binge eating – NTX: 200 mg twice daily up to 1 yr	Purge behaviors: reduced 75% (range, 52%–100%) Weekly binge-eating events: reduced 86% (range, 29%–94%) SAE: none

AN-BP, anorexia nervosa binge-purge subtype; BN, bulimia nervosa; CGI-I, Clinical Global Impressions-Improvement; CV, coefficient of variation; PCT, placebo-controlled trial; PLB, placebo; SAE, serious adverse event